Stock Analysis
Ascendis Pharma A/S (ASND) Stock Analysis
Ascendis Pharma A/S (ASND) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Ascendis Pharma A/S (ASND) currently has an AIQ Score of 72/100, indicating a bullish setup. Momentum is the strongest factor at 75/100. Value is the weakest current factor at 66/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
ASND at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $275.39 |
| AIQ Score | 72/100 |
| Overall View | Bullish |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $18.92B |
| P/E Ratio (TTM) | 17.57 |
| Forward P/E | — |
| EPS (Q3 FY2026) | $1.11 |
| Revenue (Q3 FY2026) | $367.46M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.4 |
| Volume | 826.1K |
| 52-week range | $188.07-$282.15 |
| RSI 14 | 74.7 |
| 50-Day SMA | $242.67 |
| 200-Day SMA | $239.85 |
| Analyst Price Target | $311.67 |
| Next Earnings | Feb 10, 2027 |
ASNDAscendis Pharma A/S
Healthcare / Biotechnology
Leader
Strong Relative Position
Latest quote
- Momentum75
- Value66
- Quality71
- Risk resilience72
- Sentiment—
ASND Stock Analysis Summary
Ascendis Pharma A/S (ASND) currently has an AIQ Score of 72/100, indicating a bullish setup. Momentum is the strongest factor at 75/100. Value is the weakest current factor at 66/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bullish regime, ASND has AIQ Score of 72/100 with Momentum base of 75/100 and fading Value at 66/100. Wait for component alignment before adding exposure.
Healthcare · 3.12% stock move · ASND classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is ASND Bullish or Bearish Right Now?
ASND currently has a bullish overall setup. Momentum is the strongest factor at 75/100, while Value is weakest at 66/100. The current evidence suggests a constructive setup.
- - Quality is supportive at 71/100.
- - Momentum is constructive at 75/100.
- - Risk Resilience is supportive at 72/100.
- - Price is +13.48% above its 50-day SMA.
- - Analyst target implies +13.17% upside from the latest quote.
- - No strong bearish evidence is available in the current snapshot.
Current Consensus
ASND's Technical Analysis Consensus is currently Strong Buy, with 38 buy, 2 neutral, and 6 sell votes. ASND's 14-day RSI is 74.7, which places the stock in an overbought momentum range. ASND's beta is 0.4, indicating lower market sensitivity than the broad market.
What Changed in ASND?
The largest recent change in ASND is Momentum moving up by 4.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the ASND Outlook?
The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
ASND Decision Framework
Public evidence layers, setup checks, and risk context for Ascendis Pharma A/S.
Ascendis Pharma A/S (ASND) Stock Analysis
Ascendis Pharma A/S has an AIQ Score of 72/100 in a Bullish regime. Momentum is strongest at 75/100. Beta is 0.4, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | ASND is in a Bullish AIQ regime with score 72/100. |
| Signal Conflict | The primary conflict is that momentum leads at 75/100 while value lags at 66/100. |
| Factor Evidence | Momentum 75/100 · Value 66/100 · Quality 71/100 · Risk 72/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 75/100.
Momentum is 75/100 and RSI (14) is 74.7.
ASND is in a Bullish regime at 72/100.
Risk factor is 72/100 with beta 0.4 and annual volatility 38.55%.
Current conflict: momentum leads at 75/100 while value lags at 66/100.
ASND Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
ASND Fundamentals
ASND valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
ASND Technical Analysis
ASND technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
ASND Stock Catalysts
Track ASND earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
ASND Dividend Analysis
ASND dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
ASND Financial Data
ASND revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
ASND Risk Analysis
ASND volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
ASND Stock News
ASND stock news, market tone, recent headlines, and catalyst context.
ASND vs Biotechnology Peers
Current peer cohort: ASND · AUPH · AVBP · AXSM · BBIO. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| ASND Current stock | 72/100 | 66/100 | 75/100 | 72/100 | 0.84 | 38.55% | Current |
| AUPH Aurinia Pharmaceuticals Inc. | 75/100 | 84/100 | 73/100 | 68/100 | 0.16 | 35.52% | ASND vs AUPH |
| AVBP ArriVent BioPharma, Inc. | 35/100 | — | 23/100 | 32/100 | -0.08 | 81.51% | ASND vs AVBP |
| AXSM Axsome Therapeutics, Inc. | 47/100 | 65/100 | 24/100 | 57/100 | 0.2 | 45.79% | ASND vs AXSM |
| BBIO BridgeBio Pharma, Inc. | 64/100 | 55/100 | 69/100 | 62/100 | 0.55 | 44.14% | ASND vs BBIO |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for ASND: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching ASND
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for ASND
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
ASND Stock FAQ
What is ASND stock price today?
Ascendis Pharma A/S's current stock price is $275.39. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is ASND bullish or bearish right now?
ASND's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is ASND's market cap?
ASND's market cap is $18.92B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is ASND's current P/E ratio?
ASND's current P/E ratio is 17.57 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is ASND's RSI?
ASND's 14-day RSI is 74.7 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is ASND above its 50-day and 200-day moving averages?
ASND is 13.48% from its 50-day SMA and 14.82% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is ASND's next earnings date?
ASND's next earnings date is currently listed as Feb 10, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does ASND pay a dividend?
ASND's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.